/images/ppid_59c68470-image-176007257372252784.webp)
/images/ppid_59c68470-image-177068773220034130.webp)
/images/ppid_59c68470-image-177068778557690523.webp)
/images/ppid_59c68470-image-177068760218448786.webp)
What is the story about?
Shares of Natco Pharma Ltd. surged up to 5% on Friday, October 10, in response to the Delhi High Court upholding an earlier order, allowing the company to sell a generic version of Swiss drugmaker Roche's spinal muscular atrophy (SMA) drug Risdiplam in India.
A division bench dismissed Roche’s appeal against a March 2025 single-judge order that had denied an injunction on public interest grounds, noting that the life-saving therapy must remain affordable and accessible.
Sold under the brand name Evrysdi by Roche, Risdiplam is used to treat SMA, a rare genetic disorder that causes progressive muscle weakness and loss of motor function. The latest ruling clears the path for Natco to launch its generic version immediately.
In a statement, Natco said it would release the product at a maximum retail price of ₹15,900 per bottle, a steep reduction from Roche’s imported version priced at around ₹6 lakh. The company added that it plans to offer additional discounts through a patient access programme to make the medicine even more affordable for eligible patients.
Shares of Natco Pharma are trading 4% higher on Friday at ₹845.3. The stock is flat over the last one month, but is down over 45% from its 52-week high of over ₹1,500 per share.
A division bench dismissed Roche’s appeal against a March 2025 single-judge order that had denied an injunction on public interest grounds, noting that the life-saving therapy must remain affordable and accessible.
Sold under the brand name Evrysdi by Roche, Risdiplam is used to treat SMA, a rare genetic disorder that causes progressive muscle weakness and loss of motor function. The latest ruling clears the path for Natco to launch its generic version immediately.
In a statement, Natco said it would release the product at a maximum retail price of ₹15,900 per bottle, a steep reduction from Roche’s imported version priced at around ₹6 lakh. The company added that it plans to offer additional discounts through a patient access programme to make the medicine even more affordable for eligible patients.
Shares of Natco Pharma are trading 4% higher on Friday at ₹845.3. The stock is flat over the last one month, but is down over 45% from its 52-week high of over ₹1,500 per share.
/images/ppid_a911dc6a-image-177069103696049438.webp)
/images/ppid_59c68470-image-177069004415381828.webp)
/images/ppid_59c68470-image-177069015656989662.webp)
/images/ppid_59c68470-image-177069019679222018.webp)
/images/ppid_59c68470-image-17706901166498245.webp)
/images/ppid_59c68470-image-177069008086153671.webp)
/images/ppid_59c68470-image-177069012456821934.webp)
/images/ppid_a911dc6a-image-17706892382281453.webp)
/images/ppid_a911dc6a-image-17706885616409661.webp)